The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Condition	Intervention	Phase
Obsessive-Compulsive Disorder [F03.080.600]	Drug: Memantine (drug)	Phase IV

Further study details as provided by Stanford University:

Primary Outcomes: Y-BOCS score at final study visit
Expected Total Enrollment:  15

The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer’s Disease. Memantine appears to work by regulating the activity of glutamate, one of the brain’s specialized messenger chemicals, which may play a role in OCD. All patients in the study will receive memantine; no one will receive placebo.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• at least 18 years of age
• suffering from OCD
• Y-BOCS score of 18 or greater
• taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:

• diagnosed with a mental disorder other than OCD
• requiring an atypical antipsychotic medication
• having failed more than 3 adequate trials of an SSRI or more than 1 adequate trial of an atypical antipsychotic
• taking tiagabine or pregabalin
• having had a previous trial of memantine

Please refer to this study by ClinicalTrials.gov identifier  NCT00264238

Nona Gamel, MSW      650-723-8601    gamel@stanford.edu

California
      Stanford University School of Medicine, Stanford,  California,  94305,  United States

Study chairs or principal investigators

Lorrin M Koran, MD,  Principal Investigator,  Stanford University   

Study ID Numbers:  SUSPO34313
Last Updated:  December 9, 2005
Record first received:  December 9, 2005
ClinicalTrials.gov Identifier:  NCT00264238
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2006-01-10